Drug Profile
Research Programme: capridines - AV Therapeutics
Alternative Names: BIO 131; C-1748; Capridine; Capridine-beta; INOC 005Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator New York Medical College
- Developer AV Therapeutics
- Class Nitrogen compounds
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 13 Feb 2014 Research Programme: capridine-beta is available for licensing as of 13 Feb 2014. http://www.avtherapeutics.com/company.html
- 05 Feb 2014 AV Therapeutics enters into a Good Manufacturing Practices agreement for capridine synthesis with DavosPharma